{"transactions":[{"id":683336,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":667,"derivative":{"underlying":"Common Stock","underlying_shares":112},"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683335,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":265,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683334,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":82,"price":4.55,"value":373.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8117,"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683333,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8199,"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":711136,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:02.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":7500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-300919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526300919/ownership.xml","form_type":"4"}},{"id":771804,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":779,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771803,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":398,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771802,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":79,"price":7.53,"value":594.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7954,"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771801,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":244,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8033,"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":855781,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:31:52.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":22500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001193125-26-096678","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526096678/ownership.xml","form_type":"4"}},{"id":896592,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":890,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896591,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":531,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896590,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"sale","planned":true,"acquired":false,"shares":78,"price":8.47,"value":660.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7789,"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896589,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":true,"shares":244,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7867,"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":995559,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1001,"derivative":{"underlying":"Common Stock","underlying_shares":112},"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995558,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":664,"derivative":{"underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995557,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"sale","planned":true,"acquired":false,"shares":76,"price":17.3,"value":1314.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7623,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995556,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7699,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995555,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7587,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":1061725,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1113,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}},{"id":1061724,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":796,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}},{"id":1061723,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":76,"price":16.65,"value":1265.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7455,"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}},{"id":1061722,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":111,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7531,"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}},{"id":1061721,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7420,"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}},{"id":1142450,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2025-05-19T20:05:28.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-20 reverse stock split effected on April 21, 2025."}],"balance_after":1224,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0000950170-25-074325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025074325/ownership.xml","form_type":"4"}},{"id":1142449,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2025-05-19T20:05:28.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-20 reverse stock split effected on April 21, 2025."}],"balance_after":929,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0000950170-25-074325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025074325/ownership.xml","form_type":"4"}},{"id":1142448,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-05-19T20:05:28.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":79,"price":7.28,"value":575.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-20 reverse stock split effected on April 21, 2025."}],"balance_after":7287,"source":{"system":"sec-edgar","filing":"0000950170-25-074325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025074325/ownership.xml","form_type":"4"}},{"id":1142447,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-05-19T20:05:28.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":true,"shares":111,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-20 reverse stock split effected on April 21, 2025."}],"balance_after":7366,"source":{"system":"sec-edgar","filing":"0000950170-25-074325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025074325/ownership.xml","form_type":"4"}},{"id":1142446,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-05-19T20:05:28.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":true,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-20 reverse stock split effected on April 21, 2025."}],"balance_after":7255,"source":{"system":"sec-edgar","filing":"0000950170-25-074325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025074325/ownership.xml","form_type":"4"}},{"id":1259647,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T01:07:11.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":false,"shares":8907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":26718,"derivative":{"underlying":"Common Stock","underlying_shares":8907},"source":{"system":"sec-edgar","filing":"0000950170-25-023573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025023573/ownership.xml","form_type":"4"}},{"id":1259646,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T01:07:11.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":false,"shares":2657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":21250,"derivative":{"underlying":"Common Stock","underlying_shares":2657},"source":{"system":"sec-edgar","filing":"0000950170-25-023573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025023573/ownership.xml","form_type":"4"}},{"id":1259645,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-02-20T01:07:11.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":4300,"price":0.8105,"value":3485.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142456,"source":{"system":"sec-edgar","filing":"0000950170-25-023573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025023573/ownership.xml","form_type":"4"}},{"id":1259644,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-02-20T01:07:11.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":true,"shares":8907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":146756,"source":{"system":"sec-edgar","filing":"0000950170-25-023573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025023573/ownership.xml","form_type":"4"}},{"id":1259643,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2025-02-20T01:07:11.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":true,"shares":2657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":137849,"source":{"system":"sec-edgar","filing":"0000950170-25-023573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025023573/ownership.xml","form_type":"4"}},{"id":1273732,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T21:15:03.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":650000,"derivative":{"exercise_price":0.782,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0000950170-25-017910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017025017910/ownership.xml","form_type":"4"}},{"id":1358891,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-11-19T21:21:21.000Z","date":"2024-11-15","kind":"exercise","planned":true,"acquired":false,"shares":2656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":23907,"derivative":{"underlying":"Common Stock","underlying_shares":2656},"source":{"system":"sec-edgar","filing":"0000950170-24-128631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024128631/ownership.xml","form_type":"4"}},{"id":1358890,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-11-19T21:21:21.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":878,"price":0.5407,"value":474.7346,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $0.5442, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135192,"source":{"system":"sec-edgar","filing":"0000950170-24-128631","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024128631/ownership.xml","form_type":"4"}},{"id":1358889,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-11-19T21:21:21.000Z","date":"2024-11-15","kind":"exercise","planned":true,"acquired":true,"shares":2656,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":136070,"source":{"system":"sec-edgar","filing":"0000950170-24-128631","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024128631/ownership.xml","form_type":"4"}},{"id":1379977,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-10-29T22:26:27.000Z","date":"2024-10-27","kind":"exercise","planned":true,"acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,500 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0000950170-24-118415","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024118415/ownership.xml","form_type":"4"}},{"id":1379976,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-10-29T22:26:27.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":4259,"price":0.6901,"value":2939.1359,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 4, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.6934, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":133414,"source":{"system":"sec-edgar","filing":"0000950170-24-118415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024118415/ownership.xml","form_type":"4"}},{"id":1379975,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-10-29T22:26:27.000Z","date":"2024-10-27","kind":"exercise","planned":true,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,500 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."}],"balance_after":137673,"source":{"system":"sec-edgar","filing":"0000950170-24-118415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024118415/ownership.xml","form_type":"4"}},{"id":1429189,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-08-19T21:48:36.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":false,"shares":2656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":26563,"derivative":{"underlying":"Common Stock","underlying_shares":2656},"source":{"system":"sec-edgar","filing":"0000950170-24-098719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024098719/ownership.xml","form_type":"4"}},{"id":1429188,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-08-19T21:48:36.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":873,"price":0.84,"value":733.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.8863, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":124173,"source":{"system":"sec-edgar","filing":"0000950170-24-098719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024098719/ownership.xml","form_type":"4"}},{"id":1429187,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-08-19T21:48:36.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":true,"shares":2656,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":125046,"source":{"system":"sec-edgar","filing":"0000950170-24-098719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024098719/ownership.xml","form_type":"4"}},{"id":1511090,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-05-18T00:14:50.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":false,"shares":2656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":29219,"derivative":{"underlying":"Common Stock","underlying_shares":2656},"source":{"system":"sec-edgar","filing":"0000950170-24-062052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024062052/ownership.xml","form_type":"4"}},{"id":1511089,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-05-18T00:14:50.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":843,"price":0.94,"value":792.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":122390,"source":{"system":"sec-edgar","filing":"0000950170-24-062052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024062052/ownership.xml","form_type":"4"}},{"id":1511088,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-05-18T00:14:50.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":true,"shares":2656,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":123233,"source":{"system":"sec-edgar","filing":"0000950170-24-062052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024062052/ownership.xml","form_type":"4"}},{"id":1638085,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":false,"shares":10625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":31875,"derivative":{"underlying":"Common Stock","underlying_shares":10625},"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1638084,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":35625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":35625,"derivative":{"underlying":"Common Stock","underlying_shares":35625},"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1638083,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":287905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively."}],"balance_after":287905,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":287905},"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1638082,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":213750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":213750,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":213750},"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1638081,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":3939,"price":1.08,"value":4254.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":120577,"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1638080,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2024-02-17T02:48:16.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":true,"shares":10625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":124516,"source":{"system":"sec-edgar","filing":"0000950170-24-016712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000095017024016712/ownership.xml","form_type":"4"}},{"id":1753110,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:39:10.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":false,"shares":13501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":13500,"derivative":{"underlying":"Common Stock","underlying_shares":13501},"source":{"system":"sec-edgar","filing":"0000899243-23-020076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323020076/doc4.xml","form_type":"4"}},{"id":1753109,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:39:10.000Z","date":"2023-04-27","kind":"grant","planned":true,"acquired":true,"shares":27001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":27001,"derivative":{"underlying":"Common Stock","underlying_shares":27001},"source":{"system":"sec-edgar","filing":"0000899243-23-020076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323020076/doc4.xml","form_type":"4"}},{"id":1753108,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2023-11-01T01:39:10.000Z","date":"2023-10-30","kind":"sale","planned":true,"acquired":false,"shares":4156,"price":1.35,"value":5610.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 4, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.35 to $1.385, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":113891,"source":{"system":"sec-edgar","filing":"0000899243-23-020076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323020076/doc4.xml","form_type":"4"}},{"id":1753107,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Common Stock","published_at":"2023-11-01T01:39:10.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":true,"shares":13501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,500 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."}],"balance_after":118047,"source":{"system":"sec-edgar","filing":"0000899243-23-020076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323020076/doc4.xml","form_type":"4"}},{"id":2028307,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T22:45:41.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":85000,"derivative":{"exercise_price":5.5,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0000899243-23-004207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323004207/doc4.xml","form_type":"4"}},{"id":2028306,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2023-02-07T22:45:41.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."}],"balance_after":42500,"derivative":{"underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0000899243-23-004207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924323004207/doc4.xml","form_type":"4"}},{"id":2211770,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"COMMON STOCK","published_at":"2022-07-06T23:29:30.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":63492,"price":3.15,"value":199999.8,"ownership":{"direct":true},"balance_after":104546,"source":{"system":"sec-edgar","filing":"0000899243-22-025521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924322025521/doc4.xml","form_type":"4"}},{"id":2408182,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-09T02:30:30.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":130000,"derivative":{"exercise_price":7.38,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000899243-22-005314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924322005314/doc4.xml","form_type":"4"}},{"id":2874392,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-08T23:55:18.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":26.34,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-005255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924321005255/doc4.xml","form_type":"4"}},{"id":3296549,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2020-01-31T21:06:25.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":350000,"derivative":{"exercise_price":3.3,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-20-002420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924320002420/doc4.xml","form_type":"4"}},{"id":3300080,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2020-01-28T21:06:19.000Z","date":"2020-01-26","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units are fully vested and do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units are fully vested and do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-20-002212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924320002212/doc4.xml","form_type":"4"}},{"id":3300079,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"COMMON STOCK","published_at":"2020-01-28T21:06:19.000Z","date":"2020-01-26","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":41054,"source":{"system":"sec-edgar","filing":"0000899243-20-002212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924320002212/doc4.xml","form_type":"4"}},{"id":3683761,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2019-01-29T23:55:12.000Z","date":"2019-01-26","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-002141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924319002141/doc4.xml","form_type":"4"}},{"id":3683760,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2019-01-29T23:55:12.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":84800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on January 25, 2020.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":84800,"derivative":{"exercise_price":6.01,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":84800},"source":{"system":"sec-edgar","filing":"0000899243-19-002141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924319002141/doc4.xml","form_type":"4"}},{"id":3683759,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"COMMON STOCK","published_at":"2019-01-29T23:55:12.000Z","date":"2019-01-28","kind":"sale","acquired":false,"shares":5471,"price":5.7536,"value":31477.9456,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  These shares were sold in multiple transactions at per share prices ranging from $5.75 to $5.8435.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16054,"source":{"system":"sec-edgar","filing":"0000899243-19-002141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924319002141/doc4.xml","form_type":"4"}},{"id":3683758,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"COMMON STOCK","published_at":"2019-01-29T23:55:12.000Z","date":"2019-01-26","kind":"exercise","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":21525,"source":{"system":"sec-edgar","filing":"0000899243-19-002141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924319002141/doc4.xml","form_type":"4"}},{"id":4084781,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-01-31T01:58:36.000Z","date":"2018-01-30","kind":"grant","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This Option will vest as to one third of the shares on January 30, 2019, one third on January 30, 2020 and one third on January 30, 2021."}],"balance_after":100000,"derivative":{"exercise_price":10.42,"expiration_date":"2028-01-29","underlying":"COMMON STOCK","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-002329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924318002329/doc4.xml","form_type":"4"}},{"id":4084780,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-01-31T01:58:36.000Z","date":"2018-01-30","kind":"grant","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option will vest as to 25% of the shares on January 30, 2019.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":80000,"derivative":{"exercise_price":10.42,"expiration_date":"2028-01-29","underlying":"COMMON STOCK","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-18-002329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924318002329/doc4.xml","form_type":"4"}},{"id":4084779,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"RESTRICTED STOCK UNITS","published_at":"2018-01-31T01:58:36.000Z","date":"2018-01-26","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020."}],"balance_after":40000,"derivative":{"underlying":"COMMON STOCK","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-002329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924318002329/doc4.xml","form_type":"4"}},{"id":4084778,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T01:58:36.000Z","date":"2018-01-26","kind":"sale","acquired":false,"shares":3475,"price":11.02,"value":38294.5,"ownership":{"direct":true},"balance_after":6525,"source":{"system":"sec-edgar","filing":"0000899243-18-002329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924318002329/doc4.xml","form_type":"4"}},{"id":4084777,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2018-01-31T01:58:36.000Z","date":"2018-01-26","kind":"exercise","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-18-002329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924318002329/doc4.xml","form_type":"4"}},{"id":4479173,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Restricted Stock Units","published_at":"2017-01-27T22:57:01.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-17-002129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924317002129/doc4.xml","form_type":"4"}},{"id":4479172,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and EVP"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T22:57:01.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 26, 2018.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":9.89,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-17-002129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000089924317002129/doc4.xml","form_type":"4"}}]}